Search

Displaying results 8491 - 8500 of 10000 in total
  1. Drug

    Vicasinabin

    go.drugbank.com/drugs/DB21587
    Investigational

    Vicasinabin is under investigation in clinical trial NCT04265261 (A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic

  2. Drug

    Cannabigerol

    go.drugbank.com/drugs/DB14734
    Investigational

    A natural product found in Cannabis sativa and Helichrysum species.

  3. Drug

    Cannabichromene

    go.drugbank.com/drugs/DB14735
    Investigational

    A natural product found in Cannabis sativa and Helichrysum species.

  4. Drug

    GB1211

    go.drugbank.com/drugs/DB17499
    Investigational

    GB1211 is an orally active galectin-3 (Gal-3) inhibitor.

  5. Drug

    RAPA-201

    go.drugbank.com/drugs/DB18446
    Investigational

    RAPA-201 is an autologous rapamycin-resistant T-cell therapy.

  6. Drug

    Givastomig

    go.drugbank.com/drugs/DB18618
    Investigational

    Givastomig is an anti-Claudin 18.2 and 4.1BB bispecific antibody.

    Synonyms: an anti-Claudin 18.2 and 4.1BB Bispecific Antibody
  7. Drug

    CN-201

    go.drugbank.com/drugs/DB18726
    Investigational

    CN-201 is a humanized anti-CD3/CD19 bispecific antibody.

  8. Drug

    Isoliquiritigenin

    go.drugbank.com/drugs/DB03285
    Experimental

    Isoliquiritigenin is a precursor to several flavonones in many plants.

    Synonyms: (E)-1-(2,4-Dihydroxy-phenyl)-3-(4-hydroxy-phenyl)-propenone, (E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propene-1-one
  9. Drug

    Clorgiline

    go.drugbank.com/drugs/DB04017
    Experimental

    An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.

  10. Drug

    Nisevokitug

    go.drugbank.com/drugs/DB17561
    Investigational

    and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients). … Nisevokitug is a monoclonal antibody targeted against transforming growth factor beta (TGFβ) under investigation in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety